Literature DB >> 7910941

[Experimental chemoendocrine therapy of human breast carcinoma xenograft serially transplanted into nude mice].

O Watanabe1.   

Abstract

The antitumor effect of combined chemoendocrine therapy with tamoxifen (TAM) and 5-fluorouracil (5-FU) on breast carcinoma xenograft (R-27), serially transplanted into the nude mice, was examined from the aspect of estrogen receptors (ER) and cytological features. The mice were given 6 intramuscular injections of TAM (5mg/kg) at 3-day intervals (TAM group), 3 intraperitoneal injections of 5-FU (60 mg/kg) at 4-day intervals ((5-FU group), or a combination of the two drugs (combined group). When the tumor was resected on 21 days after the initial treatment, the ER were assayed and %S was determined by flowcytometry. Furthermore, proliferative cell nuclear antigen (PCNA) was stained, and the stained cells were counted. A synergistic antitumor effect of TAN and 5-FU was found in mice given combined therapy. Reduction in the ER level was more marked in this group than in the others, but there were no significant differences in the %S value or the ratio of PCNA positive cells among the three treated groups. These results suggest that the combined effect of TAM and 5-FU has no relation to the inhibition of DNA synthesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7910941

Source DB:  PubMed          Journal:  Nihon Geka Gakkai Zasshi        ISSN: 0301-4894


  2 in total

1.  Effects of experimental chemoendocrine therapy with a combination of a pure antiestrogen and 5-fluorouracil on human breast cancer cells implanted in nude mice.

Authors:  Y Ogasawara; H Doihara; K Shiroma; Y Kanaya; N Shimizu
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Effect of combined therapy with the antiestrogen agent toremifene and local hyperthermia on breast cancer cells implanted in nude mice.

Authors:  Yoshiaki Kanaya; Hiroyoshi Doihara; Kouji Shiroma; Yutaka Ogasawara; Hiroshi Date
Journal:  Surg Today       Date:  2008-09-27       Impact factor: 2.549

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.